Nephros Inc Dossier
Qualitative Analysis
Business overview
Nephros, Inc. (Nasdaq: NEPH) is a commercial-stage water technology company that develops and sells high-performance water filtration and purification solutions. The company's core focus is on medical-grade water filtration, serving healthcare and medical markets with two primary product lines: infection control and dialysis water. Its infection control products feature microfilters (0.1 micron) and ultrafilters (0.005 micron) designed to physically retain waterborne pathogens such as Legionella, Pseudomonas, viruses, and endotoxins. In commercial markets, Nephros provides filtration solutions to improve water quality, taste, and odor, and to reduce biofilm, bacteria, and scale build-up in downstream equipment like ice machines and soft drink dispensers. The company's subsidiary, Specialty Renal Products, Inc. (SRP), is engaged in developing a second-generation hemodiafiltration system.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Entry into the Puerto Rican market targeting high-need water filtration applications across healthcare, foodservice, and hospitality sectors. The company is offering localized Spanish-language support, rapid fulfillment, and on-site installation.
Expected impact: Targets a total estimated market opportunity of $10 million, broken down into $3M from healthcare, $3M from foodservice, $1M from hotels, $1M from other hospitality, and $1M from service contracts and replacements.
A dedicated education initiative established to formalize the company's leadership in industry education regarding waterborne pathogen mitigation, facility water safety programs, and compliance-driven filtration solutions.
Expected impact: Aims to build long-term demand for filtration, services, and compliance solutions by establishing Nephros as a trusted authority in water safety.
Launch of the 19-Series PFAS Filter, a point-of-use filter designed to reduce Total PFAS, lead, asbestos, and other hazardous substances in potable water.
Expected impact: Sets a new benchmark for safer drinking water in medical, educational, foodservice, and commercial spaces, addressing the widespread presence of 'forever chemicals'.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Secures exclusive rights to market Medica's proprietary ultrafiltration technology for medical applications in the United States, which is critical to Nephros' core infection control and dialysis water filtration business.
Terms: The agreement, signed on November 21, 2025, includes minimum annual purchase commitments through 2030. Failure to meet these euro-denominated purchase levels could allow Medica to terminate the agreement.